Cost-of-illness of psoriasis - results of a German cross-sectional study
Standard
Cost-of-illness of psoriasis - results of a German cross-sectional study. / Jungen, D; Augustin, M; Langenbruch, A; Zander, N; Reich, K; Strömer, K; Thaci, D.; Purwins, S; Radtke, M; Gutknecht, M.
In: J EUR ACAD DERMATOL, Vol. 32, No. 1, 01.2018, p. 174-180.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cost-of-illness of psoriasis - results of a German cross-sectional study
AU - Jungen, D
AU - Augustin, M
AU - Langenbruch, A
AU - Zander, N
AU - Reich, K
AU - Strömer, K
AU - Thaci, D.
AU - Purwins, S
AU - Radtke, M
AU - Gutknecht, M
N1 - Bitte den Autor Jungen als internen Autor werten, wie in der Affilierung angegeben.
PY - 2018/1
Y1 - 2018/1
N2 - BACKGROUND: Though psoriasis poses a substantial chronic socio-economic burden, few studies have addressed the economic impact in Germany.OBJECTIVES: The objective was to evaluate the annual costs of psoriasis in Germany from the societal perspective.METHODS: A cross-sectional study was performed in randomly selected German dermatology practices and clinics in 2013/2014 using standardized questionnaires of illness-related costs. Costs were grouped by perspective and category as well as analysed by sex and age. Group differences were tested by non-parametric tests.RESULTS: Complete data were obtained from 1158 patients in 132 centres. Annual average costs for patients with psoriasis: total costs € 5543 ± € 8044, systemic treatment costs (paid by the statutory health insurances [SHI]) € 3733 ± € 7322, out-of-pocket costs € 224 ± € 406, total SHI costs € 4940 ± € 7533, direct costs € 5164 ± € 7581 and indirect costs € 379 ± € 2087. Significant higher costs in male and significant lower costs in 65+-year-old patients were found.CONCLUSIONS: Psoriasis induces a considerable economic burden. Between 2003 and 2014, costs have markedly shifted from hospital, out-of-pocket and indirect costs towards systemic drug costs.
AB - BACKGROUND: Though psoriasis poses a substantial chronic socio-economic burden, few studies have addressed the economic impact in Germany.OBJECTIVES: The objective was to evaluate the annual costs of psoriasis in Germany from the societal perspective.METHODS: A cross-sectional study was performed in randomly selected German dermatology practices and clinics in 2013/2014 using standardized questionnaires of illness-related costs. Costs were grouped by perspective and category as well as analysed by sex and age. Group differences were tested by non-parametric tests.RESULTS: Complete data were obtained from 1158 patients in 132 centres. Annual average costs for patients with psoriasis: total costs € 5543 ± € 8044, systemic treatment costs (paid by the statutory health insurances [SHI]) € 3733 ± € 7322, out-of-pocket costs € 224 ± € 406, total SHI costs € 4940 ± € 7533, direct costs € 5164 ± € 7581 and indirect costs € 379 ± € 2087. Significant higher costs in male and significant lower costs in 65+-year-old patients were found.CONCLUSIONS: Psoriasis induces a considerable economic burden. Between 2003 and 2014, costs have markedly shifted from hospital, out-of-pocket and indirect costs towards systemic drug costs.
KW - Journal Article
U2 - 10.1111/jdv.14543
DO - 10.1111/jdv.14543
M3 - SCORING: Journal article
C2 - 28857297
VL - 32
SP - 174
EP - 180
JO - J EUR ACAD DERMATOL
JF - J EUR ACAD DERMATOL
SN - 0926-9959
IS - 1
ER -